NEW YORK, Nov. 14, 2018 /PRNewswire/ -- Lyfebulb, a chronic
disease-focused, patient-empowerment platform that connects
patients with industry and investors to support user-driven
innovation, announced it is joining forces with Celgene (NASDAQ:
CELG) to launch Addressing Unmet Needs in MS: An Innovation
Challenge, to seek new solutions aimed at addressing the daily
challenges associated with multiple sclerosis (MS).
The Innovation Challenge will take place in May 2019 and will be open to patient
entrepreneurs—those who have been affected by MS as either a
patient, loved one or support partner—whose companies are helping
develop solutions to address an unmet need in multiple sclerosis.
The goal of the innovation challenge is to shed light on the
endeavors and ideas of patient entrepreneurs while raising
awareness about this chronic condition. Official rules and
eligibility criteria will be announced by Lyfebulb and Celgene in
early 2019. Celgene will host an Addressing Unmet Needs in MS: An
Innovation Challenge event, in Summit,
New Jersey for the challenge finalists, where a panel of
judges, including healthcare professionals, business leaders and
industry experts, will award a cash prize to the patient
entrepreneurs with the most innovative, impactful solutions.
"People living with multiple sclerosis and their caregivers
possess a deep understanding of the everyday challenges of living
with a chronic disease, giving them unique insight into creative,
achievable solutions," said Terrie
Curran, President, Celgene Inflammation and Immunology. "By
launching this innovation challenge with Lyfebulb, Celgene aims to
reinforce the value of patient-centric innovation for multiple
sclerosis by providing support to help progress the ideas of
patient entrepreneurs."
Multiple sclerosis is a chronic, often debilitating disease that
affects approximately 2.5 million people around the world. In MS,
an abnormal response of the body's immune system causes
inflammation and damage to myelin—the substance the covers nerve
fibers—as well as damage to nerves themselves. Signs and symptoms
are varied and can pose significant challenges in daily
life.
"As part of our mission to reduce the burden of living with
chronic diseases, we are thrilled to expand our focus into MS in
conjunction with Celgene," said Dr. Karin
Hehenberger, CEO and Founder of Lyfebulb. "We look forward
to engaging deeply with the MS community to better understand and
elucidate their frustrations confronted in daily life. Importantly,
we are eager to highlight those patient entrepreneurs whose
solutions may really benefit the lives of the millions of MS
patients."
About Lyfebulb
Lyfebulb is a chronic disease-focused,
patient empowerment platform that connects patients, industry
(manufacturers and payers), and investors to support user-driven
innovation and reduce the burden of chronic disease. Lyfebulb
promotes a healthy, take-charge lifestyle for those affected by
chronic disease. Grounded with its strong foundation in diabetes,
the company has expanded disease states covered into cancer,
inflammatory bowel disease, and now multiple sclerosis.
See www.lyfebulb.com, Facebook, Twitter, Instagram, Karin
Hehenberger LinkedIn, and Lyfebulb LinkedIn.
About Celgene
Celgene Corporation, headquartered in
Summit, New Jersey, is an
integrated global pharmaceutical company engaged primarily in the
discovery, development and commercialization of innovative
therapies for the treatment of cancer and inflammatory diseases
through next‐generation solutions in protein homeostasis,
immuno‐oncology, epigenetics, immunology and neuro‐inflammation.
For more information, please visit www.celgene.com. Follow
Celgene on Social Media: @Celgene, Pinterest, LinkedIn,
Facebook and YouTube.
For inquiries, please contact:
Lyfebulb:
Karin
Hehenberger, 917-575-0210
CEO and Founder
View original content to download
multimedia:http://www.prnewswire.com/news-releases/lyfebulb-partners-with-celgene-to-inspire-patient-driven-innovation-in-the-management-of-multiple-sclerosis-300749592.html
SOURCE Lyfebulb